Other oral are in FDA review and could hit the market in 2024
As for clinical outcomes, in the T2DM group, there was a significant reduction in HbA1c (decreased by 1.01% to 1.02%, placebo-adjusted) and a clinically meaningful decrease in body weight of 3.26% to 3.51% after 12 weeks of treatment
These medications include semaglutide (Ozempic, Wegovy) and dulaglutide (Trulicity) for both diabetes and weight management, and liraglutide (Victoza for diabetes, Saxenda for weight management)
Considering Renuvion After GLP-1 Weight Loss
Eli Lilly and Novo Nordisk both offer savings cards for eligible patients
1 Introduction In the past decade, obesity and related co-morbidities have become critical public health problems and serious medical conditions worldwide (1)